TLSA (Tiziana Life Sciences Ltd.) Net Profit

TLSA (Tiziana Life Sciences Ltd) - company brandmark

Tiziana Life Sciences (TLSA) develops advanced protective health solutions by utilizing streamlined biomaterial transport chains via specialized carriers. This chart of the share price reflects that the current value is -0.03. The financial model relies on capital raising, as the testing phase for new products precludes stable revenue prior to their commercialization.

TLSA (Tiziana Life Sciences) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Tiziana Life Sciences Ltd (TLSA)

- price and consensus price forecast:
Stock Quotes Tiziana Life Sciences, Ltd.|TLSA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Tiziana Life Sciences, Ltd.|TLSA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Tiziana Life Sciences|TLSA - Book Capitalization|Market Capitalization to Book Value tizianalifesciences.com|TLSA - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Tiziana Life Sciences|TLSA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Tiziana Life Sciences Ltd.|TLSA - Company Total Debt|Debts to Book Capitalization Tiziana Life Sciences, Ltd.|TLSA - Company Long-Term Debt|Company Short-Term Indebtedness Tiziana Life Sciences|Immediate Liquidity tizianalifesciences.com
- net income and valuation multiples indicators:
TLSA - Net Income
Summary company analysis:Tiziana Life Sciences
Core merchandise of Tiziana Life Sciences PLC

Tiziana Life Sciences profit reflects the final financial result after deducting all operating and tax expenses. This metric allows investors to filter out market noise and assess the actual efficiency of the business. By analyzing the company's net economic effect, one can identify historical peaks and troughs in profitability. For Tiziana Life Sciences (TLSA), this indicator confirms the ability to monetize unique patents. Monopoly pricing power over antibody delivery methods directly determines future profit growth.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PGEN: Net Income|Pharming Corp - Profit After Payment of Taxes|NKTR: Net Profit|UPB - Net Financial Result|Net Income ZBIO|Immunome Inc - Profit After Tax|Net Profit GOSS|Net Financial Result KalVista Corp|Net Profit SEPN (Septerna Inc)|Net Profit pieris.com PVLA|SVRA - Company Net Income|RIGL (Rigel Pharma) - Company Profit|ANAB: Net Profit|Astria Corp (ATXS) - Net Profit|Net Income ENGN|RAPT: Final Profit|Company Net Income Aerovate Therapeutics Inc (JBIO)|Company Net Income ACRS (Aclaris Therapeutics Inc.)|Net Profit KYTX (Kyverna)|Net Financial Result Cabaletta Bio Inc (CABA)|Ventyx Biosciences - Net Profit|Profit After Tax THTX|AVTX: Net Profit|Company Net Income Eledon Pharmaceuticals Inc. (ELDN)|Net Income AGEN|CLYM: Final Profit|Company Net Income Zura Bio Limited (ZURA)|Net Financial Result atyrpharma.com|Net Profit ADAG (Adagene Inc.)|IMA - Net Income|Shattuck Therapeutics - Net Profit|Net Financial Result Equillium, Inc. EQ|CNTB: Net Profit|Company Net Income Immunic (IMUX)|Company Net Income Atara Biotherapeutics, Inc.|Company Profit IFRX (InflaRx GmbH)|Net Profit XFOR|Net Income adicetbio.com ACET|Net Profit CELU (Celularity)|inmunebio.com (INMB) - Company Net Income|BRNS - Company Net Income|Net Financial Result Kezar Life Sciences Inc. KZR|SABS (SAB Biotherapeutics, Inc) - Net Income|AKTX: Profit After Payment of Taxes|Company Net Income Enlivex Therapeutics Ltd|Company Net Income QTTB|Company Net Income GeoVax (GOVX)|Net Financial Result Edesa Biotech Inc|Net Profit IBIO (iBio Corp)|Net Profit Carisma Therapeutics Inc CARM|XTLB - Company Net Income|Profit After Tax BOLT|HCWB: Net Profit|Aptevo Therapeutics Inc. - Final Profit|AIM (AIM ImmunoTech) - Net Profit|Net Profit Aditxt Corp|Company Net Income GRI Bio, Inc. (GRI)|XRTX (xortx.com) - Final Profit|Company Net Income Vyome Holdings HIND|REVB - Net Income|Indaptus - Net Profit|SCNI - Net Profit|CALI (calcimedica.com) - Net Income|Affimed N.V. - Final Profit|ALLK (Allakos Inc) - Net Profit|HOOKIPA (HOOK) - Net Financial Result|Company Net Income IGM Biosciences, Inc. (IGMS)|Net Income iTeos Pharma ITOS|Company Net Income Ocean Biomedical, Inc. OCEA|TCBP - Net Income|THRD: Net Income